Patents by Inventor Paul D. Robbins
Paul D. Robbins has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10751273Abstract: The present invention relates to methods of inhibiting one or more signs of aging and/or degenerative disorder in a subject in need of such treatment, which comprise administering, to the subject, an effective amount of one or more of the compounds as set forth herein. “Inhibiting a sign of aging or degenerative disorder” means reducing the risk of occurrence, delaying the onset, slowing the progression, and/or reducing the severity and/or manifestation, of a sign of aging or degenerative disorder, and includes, but is not limited to, preventing the occurrence, development or progression of a sign of aging or degenerative disorder.Type: GrantFiled: December 1, 2015Date of Patent: August 25, 2020Assignee: University of Pittsburgh—Of the Commonwealth System of Higher EducationInventors: Laura J. Niedernhofer, Paul D. Robbins, Peter Wipf
-
Patent number: 10293001Abstract: This invention relates to the use of autologous stem/progenitor cells to restore or rejuvenate adult stem cell function in a mammal, wherein the restoration or rejuvenating extends lifespan and/or improves health of the mammal. In addition, the invention also relates to compositions containing one or more regulatory factors secreted or released from isolated mammalian stem/progenitor cells and use of such compositions to extend lifespan and/or improve health of a mammal. Also provided are methods of treating, delaying, preventing or reversing progeria or related syndromes in a mammal using isolated autologous or allogeneic stem/progenitor cells and/or regulatory factors secreted or released therefrom.Type: GrantFiled: February 24, 2016Date of Patent: May 21, 2019Assignee: University of Pittsburgh—Of the Commonwealth System of Higher EducationInventors: Laura J. Niedernhofer, Mitra Lavasani, Paul D. Robbins, Johnny Huard
-
Publication number: 20160243170Abstract: This invention relates to the use of autologous stem/progenitor cells to restore or rejuvenate adult stem cell function in a mammal, wherein the restoration or rejuvenating extends lifespan and/or improves health of the mammal. In addition, the invention also relates to compositions containing one or more regulatory factors secreted or released from isolated mammalian stem/progenitor cells and use of such compositions to extend lifespan and/or improve health of a mammal. Also provided are methods of treating, delaying, preventing or reversing progeria or related syndromes in a mammal using isolated autologous or allogeneic stem/progenitor cells and/or regulatory factors secreted or released therefrom.Type: ApplicationFiled: February 24, 2016Publication date: August 25, 2016Inventors: Laura J. Niedernhofer, Mitra Lavasani, Paul D. Robbins, Johnny Huard
-
Publication number: 20160151269Abstract: The present invention relates to methods of inhibiting one or more signs of aging and/or degenerative disorder in a subject in need of such treatment, which comprise administering, to the subject, an effective amount of one or more of the compounds as set forth herein. “Inhibiting a sign of aging or degenerative disorder” means reducing the risk of occurrence, delaying the onset, slowing the progression, and/or reducing the severity and/or manifestation, of a sign of aging or degenerative disorder, and includes, but is not limited to, preventing the occurrence, development or progression of a sign of aging or degenerative disorder.Type: ApplicationFiled: December 1, 2015Publication date: June 2, 2016Applicant: University of Pittsburgh - of the Commonwealth System of Higher EducationInventors: Laura J. Niedernhofer, Paul D. Robbins, Peter Wipf
-
Patent number: 9295696Abstract: This invention relates to the use of autologous stem/progenitor cells to restore or rejuvenate adult stem cell function in a mammal, wherein the restoration or rejuvenating extends lifespan and/or improves health of the mammal. In addition, the invention also relates to compositions containing one or more regulatory factors secreted or released from isolated mammalian stem/progenitor cells and use of such compositions to extend lifespan and/or improve health of a mammal. Also provided are methods of treating, delaying, preventing or reversing progeria or related syndromes in a mammal using isolated autologous or allogeneic stem/progenitor cells and/or regulatory factors secreted or released therefrom.Type: GrantFiled: June 7, 2013Date of Patent: March 29, 2016Assignee: University of Pittsburgh—Of the Commonwealth System of Higher EducationInventors: Laura J. Niedernhofer, Mitra Lavasani, Paul D. Robbins, Johnny Huard
-
Patent number: 9220711Abstract: The present invention relates to methods of inhibiting one or more signs of aging and/or degenerative disorder in a subject in need of such treatment, which comprise administering, to the subject, an effective amount of one or more of the compounds as set forth herein. “Inhibiting a sign of aging or degenerative disorder” means reducing the risk of occurrence, delaying the onset, slowing the progression, and/or reducing the severity and/or manifestation, of a sign of aging or degenerative disorder, and includes, but is not limited to, preventing the occurrence, development or progression of a sign of aging or degenerative disorder.Type: GrantFiled: March 18, 2014Date of Patent: December 29, 2015Assignee: University of Pittsburgh—of the Commonwealth System of Higher EducationInventors: Laura J. Niedernhofer, Paul D. Robbins, Peter Wipf
-
Patent number: 8937086Abstract: The present invention relates to methods of inhibiting one or more signs of aging and/or degenerative disorder in a subject in need of such treatment, which comprise administering, to the subject, an effective amount of one or more of the compounds as set forth herein. “Inhibiting a sign of aging or degenerative disorder” means reducing the risk of occurrence, delaying the onset, slowing the progression, and/or reducing the severity and/or manifestation, of a sign of aging or degenerative disorder, and includes, but is not limited to, preventing the occurrence, development or progression of a sign of aging or degenerative disorder.Type: GrantFiled: January 14, 2011Date of Patent: January 20, 2015Assignee: University of Pittsburgh—Of the Commonwealth System of Higher EducationInventors: Laura J. Niedernhofer, Paul D. Robbins, Peter Wipf
-
Publication number: 20150018346Abstract: The present invention relates to methods of inhibiting one or more signs of aging and/or degenerative disorder in a subject in need of such treatment, which comprise administering, to the subject, an effective amount of one or more of the compounds as set forth herein. “Inhibiting a sign of aging or degenerative disorder” means reducing the risk of occurrence, delaying the onset, slowing the progression, and/or reducing the severity and/or manifestation, of a sign of aging or degenerative disorder, and includes, but is not limited to, preventing the occurrence, development or progression of a sign of aging or degenerative disorder.Type: ApplicationFiled: March 18, 2014Publication date: January 15, 2015Applicant: University of Pittsburgh - Of the Commonwealth System of Higher EducationInventors: Laura J. Niedernhofer, Paul D. Robbins, Peter Wipf
-
Publication number: 20140010801Abstract: This invention relates to the use of autologous stem/progenitor cells to restore or rejuvenate adult stem cell function in a mammal, wherein the restoration or rejuvenating extends lifespan and/or improves health of the mammal. In addition, the invention also relates to compositions containing one or more regulatory factors secreted or released from isolated mammalian stem/progenitor cells and use of such compositions to extend lifespan and/or improve health of a mammal. Also provided are methods of treating, delaying, preventing or reversing progeria or related syndromes in a mammal using isolated autologous or allogeneic stem/progenitor cells and/or regulatory factors secreted or released therefrom.Type: ApplicationFiled: June 7, 2013Publication date: January 9, 2014Inventors: Laura J. Niedernhofer, Mitra Lavasani, Paul D. Robbins, Johnny Huard
-
Publication number: 20130336935Abstract: This invention relates to the use of autologous stem/progenitor cells to restore or rejuvenate adult stem cell function in a mammal, wherein the restoration or rejuvenating extends lifespan and/or improves health of the mammal. In addition, the invention also relates to compositions containing one or more regulatory factors secreted or released from isolated mammalian stem/progenitor cells and use of such compositions to extend lifespan and/or improve health of a mammal. Also provided are methods of treating, delaying, preventing or reversing progeria or related syndromes in a mammal using isolated autologous or allogeneic stem/progenitor cells and/or regulatory factors secreted or released therefrom.Type: ApplicationFiled: June 7, 2013Publication date: December 19, 2013Inventors: Laura J. Niedernhofer, Mitra Lavasani, Paul D. Robbins, Johnny Huard
-
Publication number: 20120309817Abstract: The present invention relates to a method for treating bone pathologies comprising delivering a viral or non-viral delivery vehicle comprising genetic information (e.g. a transgene) encoding a therapeutic osteoinductive factor to target cells in vivo enabling the cells to produce the osteoinductive factor at the site of the bone pathology. The delivery is achieved by a simplified method which does not require cumbersome ex vivo techniques or additional matrix or scaffolding agents. Such viral and non-viral delivery vehicles of the present invention are derived from the following nonlimiting examples: adenoviruses, adeno-associated viruses, retroviruses, herpes simplex viruses, liposomes, and plasmids. The osteoinductive factors include, but are not limited to, growth factors, cytokines, growth factor inhibitors and cytokine inhibitors.Type: ApplicationFiled: August 15, 2012Publication date: December 6, 2012Inventors: Axel W. Baltzer, Paul D. Robbins, Chistopher H. Evans
-
Publication number: 20120004263Abstract: The present invention relates to methods of inhibiting one or more signs of aging and/or degenerative disorder in a subject in need of such treatment, which comprise administering, to the subject, an effective amount of one or more of the compounds as set forth herein. “Inhibiting a sign of aging or degenerative disorder” means reducing the risk of occurrence, delaying the onset, slowing the progression, and/or reducing the severity and/or manifestation, of a sign of aging or degenerative disorder, and includes, but is not limited to, preventing the occurrence, development or progression of a sign of aging or degenerative disorder.Type: ApplicationFiled: January 14, 2011Publication date: January 5, 2012Applicant: UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATIONInventors: Laura J. Niedernhofer, Paul D. Robbins, Peter Wipf
-
Publication number: 20110280935Abstract: The present invention relates to a method for treating bone pathologies comprising delivering a viral or non-viral delivery vehicle comprising genetic information (e.g. a transgene) encoding a therapeutic osteoinductive factor to target cells in vivo enabling the cells to produce the osteoinductive factor at the site of the bone pathology. The delivery is achieved by a simplified method which does not require cumbersome ex vivo techniques or additional matrix or scaffolding agents. Such viral and non-viral delivery vehicles of the present invention are derived from the following nonlimiting examples: adenoviruses, adeno-associated viruses, retroviruses, herpes simplex viruses, liposomes, and plasmids. The osteoinductive factors include, but are not limited to, growth factors, cytokines, growth factor inhibitors and cytokine inhibitors.Type: ApplicationFiled: June 14, 2011Publication date: November 17, 2011Inventors: Axel W. Baltzer, Paul D. Robbins, Christopher H. Evans
-
Publication number: 20100008952Abstract: The present invention relates to adenovirus-based vaccines against avian influenza viruses with pandemic potential. The present invention provides replication-defective adenoviral vectors, each having a nucleic acid encoding an influenza A polypeptide. When introduced into a subject, the expressed influenza A polypeptide induces the production of antibodies that bind to influenza. The present invention also provides methods for inducing an immune response in a subject. Subjects are administered a replication-defective adenoviral vector, wherein the vector has a nucleic acid encoding an influenza A polypeptide. When the vector is expressed in the subject, the influenza A polypeptide induces the subject to produce antibodies to influenza.Type: ApplicationFiled: July 24, 2009Publication date: January 14, 2010Inventors: Andrea Gambotto, Paul D. Robbins, Gao Wentao, Simon Barratt-Boyes, Adam Soloff
-
Publication number: 20090075902Abstract: The present invention relates to methods and compositions for reducing and/or delaying one or more signs of aging which comprise inhibiting NF-kappa B activation. It is based, at least in part, on the discovery that a peptide which inhibits IKK-? interaction with NEMO, linked to a transducing peptide, inhibits the development of various indicia of senescence in a murine model of aging, Ercc1?/? mice.Type: ApplicationFiled: May 23, 2008Publication date: March 19, 2009Inventors: Paul D. Robbins, Laura J. Niedernhofer
-
Patent number: 7264948Abstract: The present invention provides methods and compositions for enhancing channel activity to the mutant cystic fibrosis trans-membrane conductance regulator protein (CFTR). The compositions of the invention comprise polypeptides containing CFTR sub-domains that are designed to mimic the folding defect of the full length mutant CFTR proteins, resulting in competitive binding to cytoplasmic chaperones such as Hsc/Hsp70 and Hdj2. The methods of the invention comprise transduction, or recombinant expression, of CFTR polypeptides in a cell expressing mutant CFTR. The presence of the CFTR polypeptide results in a dominant effect whereby the CFTR polypeptide competes with the endogenously expressed mutant CFTR for binding to cytoplasmic chaperones such as Hsc/Hsp70 and Hdj2. Mutant CFTR proteins include, but are not limited to, ?F508 CFTR.Type: GrantFiled: August 28, 2003Date of Patent: September 4, 2007Assignee: University of PittsburghInventors: Paul D Robbins, Raymond Frizzell, Zhibao Mi, Fei Sun
-
Patent number: 7105494Abstract: The present invention relates to a method for treating bone pathologies comprising delivering a viral or non-viral delivery vehicle comprising genetic information (e.g. a transgene) encoding a therapeutic osteoinductive factor to target cells in vivo enabling the cells to produce the osteoinductive factor at the site of the bone pathology. The delivery is achieved by a simplified method which does not require cumbersome ex vivo techniques or additional matrix or scaffolding agents. Such viral and non-viral delivery vehicles of the present invention are derived from the following nonlimiting examples: adenoviruses, adeno-associated viruses, retroviruses, herpes simplex viruses, liposomes, and plasmids. The osteoinductive factors include, but are not limited to, growth factors, cytokines, growth factor inhibitors and cytokine inhibitors.Type: GrantFiled: April 28, 2000Date of Patent: September 12, 2006Assignee: University of Pittsburgh of the Commonwealth System of Higher EducationInventors: Axel W. Baltzer, Paul D. Robbins, Christopher H. Evans
-
Patent number: 7037492Abstract: Methods for introducing at least one gene encoding a product into at least one target cell of a mammalian host for use in treating the mammalian host are disclosed. These methods include employing recombinant techniques to produce a vector molecule that contains the gene encoding for the product, and infecting the target cells of the mammalian host using the DNA vector molecule. A method to produce an animal model for the study of connective tissue pathology is also disclosed.Type: GrantFiled: December 5, 2000Date of Patent: May 2, 2006Assignee: University of Pittsburgh of the Commonwealth System of Higher EducationInventors: Joseph C. Glorioso, Christopher H. Evans, Paul D. Robbins
-
Patent number: 6881825Abstract: The present invention relates to internalizing peptides which facilitate the uptake and transport of cargo into the cytoplasm and nuclei of cells as well as methods for the identification of the peptides, and methods of use for the peptides. The internalizing peptides of the present invention are selected for their ability to efficiently internalize cargo into a wide variety of cell types both in vivo and in vitro.Type: GrantFiled: August 31, 2000Date of Patent: April 19, 2005Assignee: University of Pittsburgh of The Commonwealth System of Higher EducationInventors: Paul D. Robbins, Zhibao Mi, Raymond Frizzell, Joseph C. Glorioso, Andrea Gambotto
-
Publication number: 20040220130Abstract: The present invention relates to a safe, simple, compact synthetic and potentially non-toxic vector that is comprised of two or more complementary strands of chemically-synthesized deoxyribonucleic (DNA) acid that, when annealed to one another, form a cassette for the efficient expression of single-stranded or double-stranded ribonucleic acid (RNA) molecules. The RNA molecules expressed from this synthetic vector may function as ribozymes, as antisense molecules, or as short, interfering RNA molecules. Alternatively, the RNA molecules may encode therapeutic or antigenic peptides, polypeptides, or proteins. This synthetic vector may be employed for the rapid screening of various candidate RNA molecules for their efficacy in gene silencing or other functions, or for the delivery of RNA molecules in therapeutic applications.Type: ApplicationFiled: March 24, 2004Publication date: November 4, 2004Inventors: Paul D. Robbins, Jeffrey C. Mai